Luthra A, Borkowski K R, Carruthers S G
Department of Medicine, University Hospital, London, Ontario, Canada.
Clin Pharmacol Ther. 1991 Apr;49(4):355-61. doi: 10.1038/clpt.1991.41.
Venoconstriction of the dorsal hand vein by local norepinephrine infusion was measured by the linear variable differential transformer method in 15 healthy unrelated subjects and eight pairs of monozygotic and six pairs of dizygotic twins. Incremental norepinephrine infusion produced dose-related venoconstriction. In unrelated subjects the doses of norepinephrine constricting basal vein diameter by 50% (ED50) ranged from 3.9 to 120.5 ng/min. There was a positive linear relationship between doses of norepinephrine infused and local steady-state plasma concentrations of norepinephrine achieved in each subject. The reciprocals of the slopes of these dose-concentration relationships, which reflect local norepinephrine clearance (disposition) in the vein, ranged from 0.47 to 1.86 ml/min. Plasma concentrations of norepinephrine associated with reduction of basal vein diameter by 50% (EC50) ranged from 1.4 to 110.2 ng/ml, with variability similar to that of ED50. There was a very high level of concordance in ED50, EC50, and clearance of norepinephrine within pairs of monozygotic twins but not within dizygotic twins. Differences in pharmacokinetics of infused norepinephrine exert a minor impact on overall intersubject variability. Genetic aspects of "tissue responsiveness" (i.e., vascular alpha-adrenoceptor response, smooth muscle contractility, and endothelial function) appear to be largely responsible for the wide intersubject variability in venoconstrictor responsiveness to norepinephrine.
通过线性可变差动变压器法,在15名健康无亲缘关系的受试者以及8对单卵双胞胎和6对双卵双胞胎中,测量了局部注射去甲肾上腺素后手背静脉的静脉收缩情况。递增注射去甲肾上腺素会产生剂量相关的静脉收缩。在无亲缘关系的受试者中,使基础静脉直径收缩50%(ED50)的去甲肾上腺素剂量范围为3.9至120.5纳克/分钟。在每个受试者中,注射的去甲肾上腺素剂量与局部稳态血浆去甲肾上腺素浓度之间存在正线性关系。这些剂量 - 浓度关系曲线斜率的倒数反映了静脉中局部去甲肾上腺素清除率(处置),范围为0.47至1.86毫升/分钟。与基础静脉直径减少50%(EC50)相关的血浆去甲肾上腺素浓度范围为1.4至110.2纳克/毫升,其变异性与ED50相似。在单卵双胞胎对中,ED50、EC50和去甲肾上腺素清除率的一致性非常高,但在双卵双胞胎对中并非如此。注射去甲肾上腺素的药代动力学差异对总体受试者间变异性影响较小。“组织反应性”的遗传因素(即血管α - 肾上腺素能受体反应、平滑肌收缩性和内皮功能)似乎在很大程度上导致了受试者间对去甲肾上腺素静脉收缩反应性的广泛变异性。